(AVNS) Avanos Medical - Ratings and Ratios
Feeding Tubes, Pain Pumps, Cold Therapy, Ablation, Injections
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 35.7% |
| Value at Risk 5%th | 54.6% |
| Relative Tail Risk | -7.01% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.70 |
| Alpha | -39.52 |
| CAGR/Max DD | -0.37 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.323 |
| Beta | 0.773 |
| Beta Downside | 0.727 |
| Drawdowns 3y | |
|---|---|
| Max DD | 68.85% |
| Mean DD | 39.49% |
| Median DD | 38.60% |
Description: AVNS Avanos Medical December 26, 2025
Avanos Medical, Inc. (NYSE:AVNS) is a U.S.-based medical-technology firm that designs, manufactures, and sells a range of device-based solutions for digestive health, non-opioid surgical pain, and minimally invasive interventional pain therapy across North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America.
The company’s core product lines include Mic-Key enteral feeding tubes and Corpak/NeoMed feeding systems for adult and neonatal nutrition, ON-Q and ambIT surgical pain pumps plus Game Ready cold-compression therapy for post-operative recovery, and a suite of interventional pain offerings such as COOLIEF chronic pain devices, OrthogenRx hyaluronic-acid injections for knee osteoarthritis, and Trident radio-frequency ablation platforms.
Avanos distributes its devices primarily through direct sales to hospitals, health systems, and specialty clinics, while also leveraging third-party wholesale distributors to reach broader end-user markets. The firm rebranded from Halyard Health in June 2018 and operates from its headquarters in Alpharetta, Georgia.
Recent performance indicators (FY 2023) show revenue of approximately $1.2 billion, a 5 % year-over-year increase driven largely by growth in the non-opioid pain segment, and an operating margin of roughly 12 %. Key macro drivers include rising hospital procedural volumes, an aging global population that expands demand for feeding and pain-management solutions, and sustained regulatory emphasis on opioid-sparing therapies, which together support a projected 4–6 % CAGR for the broader medical-device market through 2028.
For a deeper, data-rich assessment of AVNS’s valuation dynamics, you may find the analytics on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (-468.9m TTM) > 0 and > 6% of Revenue (6% = 42.0m TTM) |
| FCFTA 0.07 (>2.0%) and ΔFCFTA 4.81pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 29.08% (prev 38.11%; Δ -9.03pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 104.4m > Net Income -468.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.38 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (46.4m) change vs 12m ago -0.43% (target <= -2.0% for YES) |
| Gross Margin 51.76% (prev 55.51%; Δ -3.75pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 51.39% (prev 41.15%; Δ 10.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -55.08 (EBITDA TTM -439.1m / Interest Expense TTM 8.70m) >= 6 (WARN >= 3) |
Altman Z'' -6.43
| (A) 0.19 = (Total Current Assets 351.4m - Total Current Liabilities 147.9m) / Total Assets 1.07b |
| (B) -0.73 = Retained Earnings (Balance) -778.6m / Total Assets 1.07b |
| (C) -0.35 = EBIT TTM -479.2m / Avg Total Assets 1.36b |
| (D) -2.80 = Book Value of Equity -810.7m / Total Liabilities 289.7m |
| Total Rating: -6.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 36.92
| 1. Piotroski 5.0pt |
| 2. FCF Yield 12.87% |
| 3. FCF Margin 10.70% |
| 4. Debt/Equity 0.17 |
| 5. Debt/Ebitda -0.14 |
| 6. ROIC - WACC (= -68.26)% |
| 7. RoE -58.21% |
| 8. Rev. Trend -35.94% |
| 9. EPS Trend -60.98% |
What is the price of AVNS shares?
Over the past week, the price has changed by +4.19%, over one month by +4.09%, over three months by +3.54% and over the past year by -24.32%.
Is AVNS a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the AVNS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14 | 19.7% |
| Analysts Target Price | 14 | 19.7% |
| ValueRay Target Price | 9 | -23.2% |
AVNS Fundamental Data Overview January 04, 2026
P/S = 0.7415
P/B = 0.67
Beta = 1.094
Revenue TTM = 699.9m USD
EBIT TTM = -479.2m USD
EBITDA TTM = -439.1m USD
Long Term Debt = 93.4m USD (from longTermDebt, last quarter)
Short Term Debt = 18.9m USD (from shortTermDebt, last quarter)
Debt = 133.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.2m USD (from netDebt column, last quarter)
Enterprise Value = 582.2m USD (519.0m + Debt 133.7m - CCE 70.5m)
Interest Coverage Ratio = -55.08 (Ebit TTM -479.2m / Interest Expense TTM 8.70m)
FCF Yield = 12.87% (FCF TTM 74.9m / Enterprise Value 582.2m)
FCF Margin = 10.70% (FCF TTM 74.9m / Revenue TTM 699.9m)
Net Margin = -67.00% (Net Income TTM -468.9m / Revenue TTM 699.9m)
Gross Margin = 51.76% ((Revenue TTM 699.9m - Cost of Revenue TTM 337.6m) / Revenue TTM)
Gross Margin QoQ = 45.61% (prev 52.63%)
Tobins Q-Ratio = 0.55 (Enterprise Value 582.2m / Total Assets 1.07b)
Interest Expense / Debt = 1.35% (Interest Expense 1.80m / Debt 133.7m)
Taxrate = -16.67% (negative due to tax credits) (200.0k / -1.20m)
NOPAT = -559.1m (EBIT -479.2m * (1 - -16.67%)) [loss with tax shield] [negative tax rate / tax credits]
Current Ratio = 2.38 (Total Current Assets 351.4m / Total Current Liabilities 147.9m)
Debt / Equity = 0.17 (Debt 133.7m / totalStockholderEquity, last quarter 778.0m)
Debt / EBITDA = -0.14 (negative EBITDA) (Net Debt 63.2m / EBITDA -439.1m)
Debt / FCF = 0.84 (Net Debt 63.2m / FCF TTM 74.9m)
Total Stockholder Equity = 805.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -43.92% (Net Income -468.9m / Total Assets 1.07b)
RoE = -58.21% (Net Income TTM -468.9m / Total Stockholder Equity 805.5m)
RoCE = -53.31% (EBIT -479.2m / Capital Employed (Equity 805.5m + L.T.Debt 93.4m))
RoIC = -60.90% (negative operating profit) (NOPAT -559.1m / Invested Capital 918.0m)
WACC = 7.37% (E(519.0m)/V(652.7m) * Re(8.86%) + D(133.7m)/V(652.7m) * Rd(1.35%) * (1-Tc(-0.17)))
Discount Rate = 8.86% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -81.65 | Cagr: -1.07%
[DCF Debug] Terminal Value 75.96% ; FCFE base≈59.6m ; Y1≈61.9m ; Y5≈70.8m
Fair Price DCF = 23.07 (DCF Value 1.07b / Shares Outstanding 46.4m; 5y FCF grow 4.00% → 3.0% )
EPS Correlation: -60.98 | EPS CAGR: -45.18% | SUE: -4.0 | # QB: 0
Revenue Correlation: -35.94 | Revenue CAGR: -2.22% | SUE: 3.24 | # QB: 2
EPS next Quarter (2026-03-31): EPS=0.23 | Chg30d=+0.020 | Revisions Net=-1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.95 | Chg30d=+0.050 | Revisions Net=-1 | Growth EPS=+5.6% | Growth Revenue=+2.2%
Additional Sources for AVNS Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle